SCHEMBL532401

SCHEMBL532401

Cc1ccc(O)c(N2CCNCC2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 14/20 0.55
HTR3A P46098 14/20 0.55
ADRB1 P08588 5/20 0.52
HTR2A P28223 3/20 0.49
CYP1A2 P05177 2/20 0.49
ADRB2 P07550 2/20 0.49
CYP3A4 P08684 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
HRH2 P25021 2/20 0.49
HTR1B P28222 2/20 0.49
HTR2C P28335 2/20 0.49
SLC6A4 P31645 2/20 0.49
HTR7 P34969 2/20 0.49
HRH1 P35367 2/20 0.49
HTR5A P47898 2/20 0.49
HTR6 P50406 2/20 0.49
PTGS1 P23219 1/20 0.49
PTGS2 P35354 1/20 0.49
DRD2 P14416 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8699310 0.86 HTR3A (0.55) HTR1AHTR3AADRB1HTR2ACYP1A2
SCHEMBL29805912 0.81 HTR1A (0.62) HTR1AHTR3AADRB1HTR2ACYP1A2
SCHEMBL11759243 0.81 HTR5A (0.57) HTR1AADRB1HTR2AHTR7HTR5A
SCHEMBL255418 0.81 HTR1A (0.62) HTR1AHTR3AADRB1HTR2ACYP1A2
SCHEMBL12653607 0.81 LMNA (0.46)
Hydrochloric Acid SCHEMBL2959720 0.80 HTR1A (0.65) HTR1AHTR3AADRB1HTR2ACYP1A2
SCHEMBL6194571 0.79 HTR1A (0.58) HTR1AHTR3AADRB1HTR2ACYP1A2
SCHEMBL6580002 0.79 ADRB1 (0.59) HTR1AHTR3AADRB1HTR2ACYP1A2
SCHEMBL27756086 0.79 DRD2 (0.49) ADRB1HTR2AHTR5AHTR6DRD2
SCHEMBL4101709 0.79 HTR3A (0.59) HTR1AHTR3AADRB1HTR2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8669249-B2 Poly (ADP-ribose) polymerase (PARP) inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2014-03-11 US disclosed
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-04-19 US disclosed
EP-2415767-A1 Poly (ADP-ribose) Polymerase (PARP) Inhibitors Takeda Pharmaceutical Company Limited (JP) 2012-02-08 EP disclosed
WO-2010111626-A2 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120094992-A1 POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS PARP1, PARP2, PARP3 HTR1A 2476/4885HTR3A 2341/4885ADRB1 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.